JP2024102139A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024102139A5 JP2024102139A5 JP2024070307A JP2024070307A JP2024102139A5 JP 2024102139 A5 JP2024102139 A5 JP 2024102139A5 JP 2024070307 A JP2024070307 A JP 2024070307A JP 2024070307 A JP2024070307 A JP 2024070307A JP 2024102139 A5 JP2024102139 A5 JP 2024102139A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cav3 antagonist
- release component
- plasma concentration
- cav3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 101150110214 Cav3 gene Proteins 0.000 claims 16
- 239000005557 antagonist Substances 0.000 claims 16
- 230000036470 plasma concentration Effects 0.000 claims 8
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 6
- 238000013270 controlled release Methods 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000016285 Movement disease Diseases 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010044565 Tremor Diseases 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 241000284466 Antarctothoa delta Species 0.000 claims 2
- 239000011324 bead Substances 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 201000006517 essential tremor Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 230000002618 waking effect Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862740755P | 2018-10-03 | 2018-10-03 | |
| US62/740,755 | 2018-10-03 | ||
| US201862780049P | 2018-12-14 | 2018-12-14 | |
| US62/780,049 | 2018-12-14 | ||
| JP2021518473A JP7480131B2 (ja) | 2018-10-03 | 2019-10-03 | （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置 |
| PCT/US2019/054498 WO2020072773A1 (en) | 2018-10-03 | 2019-10-03 | Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518473A Division JP7480131B2 (ja) | 2018-10-03 | 2019-10-03 | （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024102139A JP2024102139A (ja) | 2024-07-30 |
| JP2024102139A5 true JP2024102139A5 (enExample) | 2025-01-27 |
Family
ID=70055875
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518473A Active JP7480131B2 (ja) | 2018-10-03 | 2019-10-03 | （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置 |
| JP2024070307A Pending JP2024102139A (ja) | 2018-10-03 | 2024-04-24 | （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518473A Active JP7480131B2 (ja) | 2018-10-03 | 2019-10-03 | （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US12383539B2 (enExample) |
| EP (1) | EP3860571A4 (enExample) |
| JP (2) | JP7480131B2 (enExample) |
| KR (1) | KR20210087459A (enExample) |
| CN (1) | CN113164393A (enExample) |
| AU (2) | AU2019355021B2 (enExample) |
| BR (1) | BR112021006398A2 (enExample) |
| CA (1) | CA3115235A1 (enExample) |
| IL (2) | IL300798B2 (enExample) |
| MX (2) | MX2021003706A (enExample) |
| TW (1) | TWI879741B (enExample) |
| WO (1) | WO2020072773A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017070680A1 (en) | 2015-10-22 | 2017-04-27 | Cavion Llc | Methods for treating angelman syndrome and related disorders |
| US11324733B2 (en) | 2017-04-26 | 2022-05-10 | Cavion, Inc. | Methods for improving memory and cognition and for treating memory and cognitive disorders |
| TWI879741B (zh) | 2018-10-03 | 2025-04-11 | 美商卡凡恩公司 | 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫 |
| KR20220066252A (ko) | 2019-07-11 | 2022-05-24 | 프락시스 프리시젼 메디신즈, 인크. | T형 칼슘 채널 조절제의 제형 및 이의 사용 방법 |
| TWI870475B (zh) * | 2019-10-02 | 2025-01-21 | 美商卡凡恩公司 | 用於治療神經毒性之方法及材料 |
| IL297642A (en) * | 2020-04-29 | 2022-12-01 | Praxis Prec Medicines Inc | Methods for using t-type calcium channel modulators |
| WO2022251812A1 (en) * | 2021-05-24 | 2022-12-01 | Cavion, Inc. | Method of treating essential tremor |
| EP4673132A1 (en) * | 2023-03-02 | 2026-01-07 | Praxis Precision Medicines, Inc. | Methods of treating essential tremor |
| IL322960A (en) * | 2023-03-02 | 2025-10-01 | Praxis Prec Medicines Inc | High-strength single-unit dosage formulations and methods of using them |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100389752C (zh) * | 1978-04-21 | 2008-05-28 | 莱博法姆公司 | 控释组合物 |
| CA1319144C (en) | 1986-11-14 | 1993-06-15 | Quirico Branca | Tetrahydronaphthalene derivatives |
| WO1993004047A1 (en) | 1991-08-16 | 1993-03-04 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
| BR9707529A (pt) | 1996-02-14 | 2000-01-04 | Isis Pharmaceuticals Inc | Oligunucleotìdeo especificamente hibridizável com dna ou rna. |
| AU2001235363A1 (en) | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Mibefradil analogues and their use |
| WO2002082970A2 (en) | 2001-04-06 | 2002-10-24 | The Research Foundation Of The City University Of New York | Diagnosis and treatment of neural disease and injury using microvoltammetry |
| JP4491240B2 (ja) | 2002-01-17 | 2010-06-30 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | Ｉｇｆｂｐ−２およびｉｇｆｂｐ−５を阻害する二重特異性アンチセンスオリゴヌクレオチド、並びにこれらの使用方法 |
| US7347101B2 (en) | 2002-07-01 | 2008-03-25 | University Of Manitoba | Measuring strain in a structure using a sensor having an electromagnetic resonator |
| US20060003985A1 (en) | 2002-10-17 | 2006-01-05 | Renger John J | Enhancement of sleep with t-type calcium channel antagonists |
| US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
| EP1721607A1 (en) * | 2003-03-21 | 2006-11-15 | Dynogen Pharmaceuticals, Inc. | Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators |
| US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
| WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
| KR100610731B1 (ko) | 2004-02-24 | 2006-08-09 | 한국과학기술연구원 | Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법 |
| US7504431B2 (en) | 2004-04-16 | 2009-03-17 | Bristol-Myers Squibb Company | Sulfonyl amide inhibitors of calcium channel function |
| ATE552233T1 (de) | 2004-08-20 | 2012-04-15 | Univ Virginia Patent Found | T-typ-calciumkanalinhibitoren |
| JP2008510730A (ja) | 2004-08-20 | 2008-04-10 | ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン | Ｔ型カルシウムチャネルブロッカーおよび疾患の治療 |
| EP1858520B1 (en) | 2005-03-09 | 2011-10-05 | Merck Sharp & Dohme Corp. | Quinazolinone t-type calcium channel antagonists |
| AU2006262101A1 (en) | 2005-06-23 | 2007-01-04 | Merck & Co., Inc. | 3-fluoro-piperidine T-type calcium channel antagonists |
| AU2006263564A1 (en) | 2005-06-29 | 2007-01-04 | Merck Sharp & Dohme Corp. | 4-fluoro-piperidine T-type calcium channel antagonists |
| US7643104B2 (en) | 2005-07-14 | 2010-01-05 | Teijin Chemicals, Ltd. | Foamed resin sheet and liquid crystal display |
| KR100654328B1 (ko) | 2005-08-26 | 2006-12-08 | 한국과학기술연구원 | 피페라지닐알킬피라졸계 ｔ-타입 칼슘 채널 억제 화합물 및이의 제조방법 |
| US20070197523A1 (en) | 2005-12-22 | 2007-08-23 | Icagen, Inc. | Calcium channel antagonists |
| KR20080108539A (ko) | 2006-04-12 | 2008-12-15 | 머크 앤드 캄파니 인코포레이티드 | 피리딜 아미드 ｔ-형 칼슘 채널 길항제 |
| KR100743255B1 (ko) | 2006-05-04 | 2007-07-27 | 한국과학기술연구원 | Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체 |
| KR100749843B1 (ko) | 2006-07-13 | 2007-08-21 | 한국과학기술연구원 | Ｔ-타입 칼슘 채널에 억제 활성을 지닌 신규2,4-디옥소-퀴나졸린 유도체 및 이의 제조방법 |
| KR100969686B1 (ko) | 2006-08-07 | 2010-07-14 | 한국과학기술연구원 | 신규한 티아졸계 화합물 및 이를 함유하는 ｔ-형 칼슘 채널저해제 |
| JP2010503678A (ja) | 2006-09-15 | 2010-02-04 | シェーリング コーポレイション | アゼチジノン誘導体およびその使用方法 |
| US20080070892A1 (en) | 2006-09-15 | 2008-03-20 | Harris Joel M | Treating pain, diabetes, and disorders of lipid metabolism |
| CA2663500A1 (en) | 2006-09-15 | 2008-03-20 | Schering Corporation | Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism |
| CN101534818A (zh) | 2006-09-15 | 2009-09-16 | 先灵公司 | 用于治疗疼痛和脂类代谢疾病的氮杂环丁烷和氮杂环丁酮衍生物 |
| CN101583612A (zh) | 2006-09-15 | 2009-11-18 | 先灵公司 | 治疗脂质代谢障碍的氮杂环丁酮衍生物 |
| WO2008050200A1 (en) | 2006-10-24 | 2008-05-02 | Pfizer Products Inc. | Oxadiazole compounds as calcium channel antagonists |
| WO2008112715A2 (en) | 2007-03-12 | 2008-09-18 | Vm Discovery Inc. | Novel agents of calcium ion channel modulators |
| US20080227823A1 (en) | 2007-03-12 | 2008-09-18 | Hassan Pajouhesh | Amide derivatives as calcium channel blockers |
| WO2008117148A1 (en) | 2007-03-23 | 2008-10-02 | Pfizer Products Inc. | Substituted oxadiazole analogs as calcium channel antagonists |
| WO2008138126A1 (en) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
| KR100863239B1 (ko) | 2007-05-23 | 2008-10-15 | 한국과학기술연구원 | 신규한 2-이미노-1,3-티아졸린계 화합물 및 이를 함유하는ｔ-형 칼슘 채널 저해제 |
| AU2008275674A1 (en) | 2007-07-10 | 2009-01-15 | Merck & Co., Inc. | Quinazolinone T-type calcium channel antagonists |
| KR101079459B1 (ko) | 2007-09-14 | 2011-11-03 | 이화여자대학교 산학협력단 | 신규한 화합물, 이의 제조방법 및 이를 포함하는 통증억제용 조성물 |
| WO2009054984A1 (en) | 2007-10-24 | 2009-04-30 | Merck & Co., Inc. | Heterocycle phenyl amide t-type calcium channel antagonists |
| JP2011500808A (ja) | 2007-10-24 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 複素環アミドｔ型カルシウムチャネルアンタゴニスト |
| WO2009054982A1 (en) | 2007-10-24 | 2009-04-30 | Merck & Co., Inc. | Pyrazinyl amide t-type calcium channel antagonists |
| WO2009056934A1 (en) | 2007-10-31 | 2009-05-07 | Pfizer Products Inc. | 1,4-dihydronaphthyridine derivatives |
| KR100917037B1 (ko) | 2007-11-01 | 2009-09-10 | 한국과학기술연구원 | 피라졸릴카르복스아미도알킬피페라진 유도체 및 이의제조방법 |
| US20090270413A1 (en) | 2008-04-28 | 2009-10-29 | Galemmo Jr Robert | Di-t-butylphenyl piperazines as calcium channel blockers |
| WO2009133128A1 (en) | 2008-04-29 | 2009-11-05 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
| US20090298834A1 (en) | 2008-06-02 | 2009-12-03 | Hassan Pajouhesh | 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers |
| US8377968B2 (en) | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
| KR101014887B1 (ko) | 2008-06-26 | 2011-02-15 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 이미다졸릴알킬카르보닐유도체 및 그의 제조방법 |
| KR20100005476A (ko) | 2008-07-07 | 2010-01-15 | 한국과학기술연구원 | Ｔ-형 칼슘 채널에 활성을 지닌 신규 아이소인돌리논유도체 및 이의 제조방법 |
| US20100137403A1 (en) | 2008-07-10 | 2010-06-03 | Scott Malstrom | Method for enhancing cognition or inhibiting cognitive decline |
| KR101052620B1 (ko) | 2008-08-28 | 2011-07-29 | 한국과학기술연구원 | 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｔ-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물 |
| KR101052065B1 (ko) | 2008-10-15 | 2011-07-27 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법 |
| TW201028421A (en) | 2009-01-15 | 2010-08-01 | Abbott Lab | Novel benzenesulfonamides as calcium channel blockers |
| MX344725B (es) | 2009-06-05 | 2017-01-05 | Tau Therapeutics Llc * | Metodo entrelazado para tratar cancer o una condicion precancerosa. |
| EP2476308A2 (en) | 2009-08-12 | 2012-07-18 | Carlos Alberto Barcelo Rojas | Bioelectronic system |
| WO2011093393A1 (ja) | 2010-01-29 | 2011-08-04 | 国立大学法人岡山大学 | Dravet症候群の発症可能性の判定方法およびその利用 |
| US8575361B2 (en) | 2010-03-02 | 2013-11-05 | Concert Pharmaceuticals Inc. | Tetrahydronaphthalene derivatives |
| WO2012032415A2 (en) | 2010-09-08 | 2012-03-15 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin |
| WO2012094612A1 (en) | 2011-01-07 | 2012-07-12 | Zenyaku Kogyo Kabushikikaisha | Method of treating essential tremor |
| CA2872876A1 (en) | 2012-05-08 | 2013-11-14 | Zafgen, Inc. | Treating hypothalamic obesity with metap2 inhibitors |
| JP2016506248A (ja) | 2013-01-10 | 2016-03-03 | ティーエーユー・セラピューティクス・エルエルシー | 癌の処置のためのｔ型カルシウムチャネル阻害剤 |
| US10292989B2 (en) | 2014-03-28 | 2019-05-21 | University Of Virginia Patent Foundation | General anesthetics that are not neurotoxic |
| CA2953225A1 (en) | 2015-05-26 | 2016-12-01 | Isa Odidi | Controlled extended release pregabalin |
| KR101679262B1 (ko) | 2015-06-08 | 2016-11-24 | 한국과학기술연구원 | 4-이소프로필크로만-3-올 화합물 |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| US9634019B1 (en) * | 2015-10-01 | 2017-04-25 | Silicon Storage Technology, Inc. | Non-volatile split gate memory cells with integrated high K metal gate, and method of making same |
| WO2017070680A1 (en) | 2015-10-22 | 2017-04-27 | Cavion Llc | Methods for treating angelman syndrome and related disorders |
| CN109069480A (zh) * | 2015-12-30 | 2018-12-21 | 阿达玛斯医药公司 | 用于治疗与癫痫相关的病症的方法和组合物 |
| US11324733B2 (en) | 2017-04-26 | 2022-05-10 | Cavion, Inc. | Methods for improving memory and cognition and for treating memory and cognitive disorders |
| AU2018260693B2 (en) | 2017-04-26 | 2024-01-11 | Cavion, Inc. | Methods for treating Dravet syndrome |
| GB2571978A (en) | 2018-03-15 | 2019-09-18 | Andre Fisahn | Uses, compositions and methods |
| TWI879741B (zh) * | 2018-10-03 | 2025-04-11 | 美商卡凡恩公司 | 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫 |
| KR20220066252A (ko) * | 2019-07-11 | 2022-05-24 | 프락시스 프리시젼 메디신즈, 인크. | T형 칼슘 채널 조절제의 제형 및 이의 사용 방법 |
| TWI870475B (zh) | 2019-10-02 | 2025-01-21 | 美商卡凡恩公司 | 用於治療神經毒性之方法及材料 |
-
2019
- 2019-10-03 TW TW108135951A patent/TWI879741B/zh active
- 2019-10-03 WO PCT/US2019/054498 patent/WO2020072773A1/en not_active Ceased
- 2019-10-03 MX MX2021003706A patent/MX2021003706A/es unknown
- 2019-10-03 KR KR1020217013251A patent/KR20210087459A/ko active Pending
- 2019-10-03 CN CN201980079029.4A patent/CN113164393A/zh active Pending
- 2019-10-03 US US17/282,730 patent/US12383539B2/en active Active
- 2019-10-03 IL IL300798A patent/IL300798B2/en unknown
- 2019-10-03 IL IL282006A patent/IL282006B2/en unknown
- 2019-10-03 JP JP2021518473A patent/JP7480131B2/ja active Active
- 2019-10-03 EP EP19868543.0A patent/EP3860571A4/en active Pending
- 2019-10-03 CA CA3115235A patent/CA3115235A1/en active Pending
- 2019-10-03 AU AU2019355021A patent/AU2019355021B2/en active Active
- 2019-10-03 BR BR112021006398A patent/BR112021006398A2/pt not_active Application Discontinuation
-
2021
- 2021-03-29 MX MX2025002145A patent/MX2025002145A/es unknown
- 2021-05-06 US US17/313,750 patent/US11311522B1/en active Active
-
2024
- 2024-04-24 JP JP2024070307A patent/JP2024102139A/ja active Pending
- 2024-12-06 AU AU2024278171A patent/AU2024278171A1/en active Pending
-
2025
- 2025-04-21 US US19/184,847 patent/US20250312323A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024102139A5 (enExample) | ||
| JP4846063B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| EP2167099B1 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine | |
| JP2019218389A (ja) | 代謝障害を治療するための組成物および方法 | |
| TW200412934A (en) | Pharmaceutical formulations of modafinil | |
| JP2505944B2 (ja) | （Ｓ）―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物 | |
| US20110172210A1 (en) | Method for titrating clozapine | |
| MX2010013503A (es) | Composicion de topiramato/fentermina de baja dosis y metodos de uso de la misma. | |
| CN107205950B (zh) | 金刚烷胺组合物的施用方法 | |
| BR112020008128A2 (pt) | comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos | |
| JP2016074728A (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| JP2015517994A (ja) | ハロフジノンの剤形およびその使用 | |
| JP3168543B2 (ja) | バスピロン：睡眠誘起性無呼吸症剤 | |
| WO1996011682A1 (en) | Preventive and remedy for type i allergic diseases | |
| BG64614B1 (bg) | Използване на прамипексол при лечение на синдрома на неспокойни крака | |
| JPWO2020072773A5 (enExample) | ||
| JPWO2021211489A5 (enExample) | ||
| WO2020183020A1 (en) | Capsid assembly modulator solid formulation | |
| JP3227578B2 (ja) | 睡眠誘起性無呼吸症治療剤 | |
| EP1503746B1 (en) | Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders | |
| JP6420923B1 (ja) | 医薬 | |
| KR20160025075A (ko) | 구강내 속붕해 필름 조성물 및 그 제조방법 | |
| RU2837048C1 (ru) | Долгосрочный реабсорбируемый подкожный имплантат с устойчивым высвобождением предварительно концентрированного фармакологически активного вещества в полимере для лечения болезни паркинсона | |
| WO2025194118A1 (en) | Formulations and methods for alleviating sleep disorders | |
| TWI461192B (zh) | 降低血脂異常病患之糖化血色素的醫藥組成物 |